The therapeutic effects of PJ34. [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)- N,N-dimethylacetamide, HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation

Gwen S. Scott, Rhonda B. Kean, Tatiana Mikheeva, Marzena J. Fabis, Jon G. Mabley, Csaba Szabo, D. Craig Hooper

Research output: Contribution to journalArticle

56 Citations (Scopus)

Abstract

Poly(ADP-ribose) polymerase (PARP) activity has been implicated in the pathogenesis of several central nervous system (CNS) disorders. For example, the presence of extensive poly-(ADP)ribosylation in CNS tissues from animals with experimental allergic encephalomyelitis (EAE) indicates that PARP activity may be involved in this inflammatory disease process. Using PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N, N-dimethylacetamide. HCl], a selective PARP inhibitor, we studied the mechanisms through which PARP activity may contribute to the onset of acute EAE. PLSJL mice immunized with myelin antigens were treated with PJ34, and the effects on the progression of EAE and several other parameters relevant to the disease process were assessed. PJ34 exerted therapeutic effects at the onset of EAE that were associated with reduced CNS inflammation and the maintenance of neurovascular integrity. Expression of genes encoding the intercellular adhesion molecule-1 (ICAM-1) and the inflammatory mediators interferon-γ, tumor necrosis factor-α, and inducible nitric-oxide synthase were decreased in CNS tissues from drug-treated animals. Administration of PJ34 biased the class of myelin basic protein (MBP)-specific antibodies elicited from IgG2a to IgG1 and IgG2b and modulated antigen-specific T-cell reactivity. Therefore, the mode of action of PJ34 at the onset of EAE is likely mediated by a shift in the MBP-specific immune response from a proinflammatory Th1 toward an anti-inflammatory Th2 phenotype.

Original languageEnglish (US)
Pages (from-to)1053-1061
Number of pages9
JournalJournal of Pharmacology and Experimental Therapeutics
Volume310
Issue number3
DOIs
StatePublished - Sep 2004
Externally publishedYes

Fingerprint

Immunomodulation
Autoimmune Experimental Encephalomyelitis
Therapeutic Uses
Poly(ADP-ribose) Polymerases
Nerve Tissue
Myelin Basic Protein
Central Nervous System
Central Nervous System Agents
Antigens
Central Nervous System Diseases
Nitric Oxide Synthase Type II
Intercellular Adhesion Molecule-1
Myelin Sheath
Adenosine Diphosphate
Interferons
Anti-Inflammatory Agents
Tumor Necrosis Factor-alpha
Immunoglobulin G
Maintenance
N-(oxo-5,6-dihydrophenanthridin-2-yl)-N,N-dimethylacetamide hydrochloride

ASJC Scopus subject areas

  • Pharmacology

Cite this

The therapeutic effects of PJ34. [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)- N,N-dimethylacetamide, HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation. / Scott, Gwen S.; Kean, Rhonda B.; Mikheeva, Tatiana; Fabis, Marzena J.; Mabley, Jon G.; Szabo, Csaba; Hooper, D. Craig.

In: Journal of Pharmacology and Experimental Therapeutics, Vol. 310, No. 3, 09.2004, p. 1053-1061.

Research output: Contribution to journalArticle

@article{03f7cc197e464a1c9111835df46d0d30,
title = "The therapeutic effects of PJ34. [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)- N,N-dimethylacetamide, HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation",
abstract = "Poly(ADP-ribose) polymerase (PARP) activity has been implicated in the pathogenesis of several central nervous system (CNS) disorders. For example, the presence of extensive poly-(ADP)ribosylation in CNS tissues from animals with experimental allergic encephalomyelitis (EAE) indicates that PARP activity may be involved in this inflammatory disease process. Using PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N, N-dimethylacetamide. HCl], a selective PARP inhibitor, we studied the mechanisms through which PARP activity may contribute to the onset of acute EAE. PLSJL mice immunized with myelin antigens were treated with PJ34, and the effects on the progression of EAE and several other parameters relevant to the disease process were assessed. PJ34 exerted therapeutic effects at the onset of EAE that were associated with reduced CNS inflammation and the maintenance of neurovascular integrity. Expression of genes encoding the intercellular adhesion molecule-1 (ICAM-1) and the inflammatory mediators interferon-γ, tumor necrosis factor-α, and inducible nitric-oxide synthase were decreased in CNS tissues from drug-treated animals. Administration of PJ34 biased the class of myelin basic protein (MBP)-specific antibodies elicited from IgG2a to IgG1 and IgG2b and modulated antigen-specific T-cell reactivity. Therefore, the mode of action of PJ34 at the onset of EAE is likely mediated by a shift in the MBP-specific immune response from a proinflammatory Th1 toward an anti-inflammatory Th2 phenotype.",
author = "Scott, {Gwen S.} and Kean, {Rhonda B.} and Tatiana Mikheeva and Fabis, {Marzena J.} and Mabley, {Jon G.} and Csaba Szabo and Hooper, {D. Craig}",
year = "2004",
month = "9",
doi = "10.1124/jpet.103.063214",
language = "English (US)",
volume = "310",
pages = "1053--1061",
journal = "Journal of Pharmacology and Experimental Therapeutics",
issn = "0022-3565",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "3",

}

TY - JOUR

T1 - The therapeutic effects of PJ34. [N-(6-Oxo-5,6-dihydrophenanthridin-2-yl)- N,N-dimethylacetamide, HCl], a selective inhibitor of poly(ADP-ribose) polymerase, in experimental allergic encephalomyelitis are associated with immunomodulation

AU - Scott, Gwen S.

AU - Kean, Rhonda B.

AU - Mikheeva, Tatiana

AU - Fabis, Marzena J.

AU - Mabley, Jon G.

AU - Szabo, Csaba

AU - Hooper, D. Craig

PY - 2004/9

Y1 - 2004/9

N2 - Poly(ADP-ribose) polymerase (PARP) activity has been implicated in the pathogenesis of several central nervous system (CNS) disorders. For example, the presence of extensive poly-(ADP)ribosylation in CNS tissues from animals with experimental allergic encephalomyelitis (EAE) indicates that PARP activity may be involved in this inflammatory disease process. Using PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N, N-dimethylacetamide. HCl], a selective PARP inhibitor, we studied the mechanisms through which PARP activity may contribute to the onset of acute EAE. PLSJL mice immunized with myelin antigens were treated with PJ34, and the effects on the progression of EAE and several other parameters relevant to the disease process were assessed. PJ34 exerted therapeutic effects at the onset of EAE that were associated with reduced CNS inflammation and the maintenance of neurovascular integrity. Expression of genes encoding the intercellular adhesion molecule-1 (ICAM-1) and the inflammatory mediators interferon-γ, tumor necrosis factor-α, and inducible nitric-oxide synthase were decreased in CNS tissues from drug-treated animals. Administration of PJ34 biased the class of myelin basic protein (MBP)-specific antibodies elicited from IgG2a to IgG1 and IgG2b and modulated antigen-specific T-cell reactivity. Therefore, the mode of action of PJ34 at the onset of EAE is likely mediated by a shift in the MBP-specific immune response from a proinflammatory Th1 toward an anti-inflammatory Th2 phenotype.

AB - Poly(ADP-ribose) polymerase (PARP) activity has been implicated in the pathogenesis of several central nervous system (CNS) disorders. For example, the presence of extensive poly-(ADP)ribosylation in CNS tissues from animals with experimental allergic encephalomyelitis (EAE) indicates that PARP activity may be involved in this inflammatory disease process. Using PJ34 [N-(6-oxo-5,6-dihydrophenanthridin-2-yl)-N, N-dimethylacetamide. HCl], a selective PARP inhibitor, we studied the mechanisms through which PARP activity may contribute to the onset of acute EAE. PLSJL mice immunized with myelin antigens were treated with PJ34, and the effects on the progression of EAE and several other parameters relevant to the disease process were assessed. PJ34 exerted therapeutic effects at the onset of EAE that were associated with reduced CNS inflammation and the maintenance of neurovascular integrity. Expression of genes encoding the intercellular adhesion molecule-1 (ICAM-1) and the inflammatory mediators interferon-γ, tumor necrosis factor-α, and inducible nitric-oxide synthase were decreased in CNS tissues from drug-treated animals. Administration of PJ34 biased the class of myelin basic protein (MBP)-specific antibodies elicited from IgG2a to IgG1 and IgG2b and modulated antigen-specific T-cell reactivity. Therefore, the mode of action of PJ34 at the onset of EAE is likely mediated by a shift in the MBP-specific immune response from a proinflammatory Th1 toward an anti-inflammatory Th2 phenotype.

UR - http://www.scopus.com/inward/record.url?scp=4243068535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=4243068535&partnerID=8YFLogxK

U2 - 10.1124/jpet.103.063214

DO - 10.1124/jpet.103.063214

M3 - Article

VL - 310

SP - 1053

EP - 1061

JO - Journal of Pharmacology and Experimental Therapeutics

JF - Journal of Pharmacology and Experimental Therapeutics

SN - 0022-3565

IS - 3

ER -